EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has reaffirmed a Buy rating on VolitionRX (AMEX:VNRX) with a maintained price target of $4.5.
March 27, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tim Moore reaffirmed a Buy rating on VolitionRX with a steady price target of $4.5, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and the maintenance of a $4.5 price target by a reputable analyst like Tim Moore from EF Hutton could instill confidence among investors and potentially lead to a positive short-term impact on VolitionRX's stock price. The analyst's bullish stance suggests a strong belief in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100